Wang et al. reported that PRDM1 attenuated glioma malignancy by negatively modulating Wnt/b-catenin signaling and this modulation was dependent on the Wnt inhibitor Dkk1 (Wang et al., 2013). Here, PRDM1 is linked to glioma.